Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00786669 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
A Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00786669 is a Phase 1 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 13 participants.
The verdict
NCT00786669, a Phase 1 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety and of adding bevacizumab to the established regimen of vincristine, oral irinotecan, and temozolomide (VOIT) and see what effects it has in pediatric patients with relapsed or refractory solid tumors.
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
- DRUG Vincristine
- DRUG Irinotecan
- DRUG Cefixime
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00786669
The ClinicalTrials.gov registry entry for NCT00786669 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00786669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00786669 about?
NCT00786669 is a clinical study titled "A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors". The purpose of this research study is to test the safety and of adding bevacizumab to the established regimen of vincristine, oral irinotecan, and temozolomide (VOIT) and see what effects it has in pediatric patients with relapsed or refractory solid tumors.
What is the current status of trial NCT00786669?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2008-10. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00786669?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG), Vincristine (DRUG), Irinotecan (DRUG), Cefixime (DRUG).
Who is sponsoring clinical trial NCT00786669?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.